Alternatives to Rezdiffra (Resmetirom) If You Can't Fill Your Prescription

Rezdiffra (resmetirom) is a breakthrough medication — the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis. But for some patients, filling it is a challenge. Insurance may deny coverage, the cost may be prohibitive, or the prior authorization process may take too long when you need treatment now.

The good news: the treatment landscape for MASH expanded significantly in 2025. There is now a second FDA-approved option, along with several off-label medications that hepatologists have been using for years. This guide breaks down your options — with honest information about what works and what the tradeoffs are.

Important: Always discuss any medication changes with your hepatologist or gastroenterologist. MASH is a progressive liver disease, and treatment decisions should be based on your specific fibrosis stage, comorbidities, and overall health.

FDA-Approved Alternatives for MASH

Semaglutide (Wegovy) — Approved August 2025

In August 2025, the FDA approved semaglutide (Wegovy, 2.4 mg weekly injection) as a second treatment for adults with MASH and moderate to advanced fibrosis (F2-F3). Semaglutide is a GLP-1 receptor agonist — the same class of drug used for type 2 diabetes and obesity management. In the Phase 3 ESSENSE trial, semaglutide demonstrated significant improvements in both MASH resolution and fibrosis staging.

Who it may be best for: Patients with MASH who also have obesity, type 2 diabetes, or cardiovascular risk. It promotes weight loss, which amplifies liver benefit. It requires a weekly injection rather than a daily pill.

Tradeoffs vs. Rezdiffra: Semaglutide is injectable (weekly), while Rezdiffra is a daily oral tablet. Both are specialty medications with high list prices and similar access barriers. However, if you are already taking semaglutide for diabetes or obesity, your doctor may prioritize it for MASH treatment rather than adding a second drug.

Off-Label Alternatives (Not FDA-Approved for MASH)

For patients who cannot access Rezdiffra or semaglutide, hepatologists may recommend off-label therapies that have evidence supporting use in MASH — though none match Rezdiffra's specific mechanism of action or its proven fibrosis improvement data.

Pioglitazone — A Decades-Old Generic Option

Pioglitazone is a PPAR-gamma agonist approved for type 2 diabetes but used off-label in NASH/MASH. In clinical studies, pioglitazone has shown histological improvement in liver inflammation and steatosis, and approximately 51% of patients achieved MASH resolution in one trial. The American Association for the Study of Liver Diseases (AASLD) guidelines acknowledge its use in appropriate patients.

Cost: Generic pioglitazone is very affordable — typically $4–$15 per month, available at most retail pharmacies without specialty pharmacy hassle.

Side effects to know: Weight gain, fluid retention, increased risk of fractures, and a possible association with bladder cancer with long-term use (especially at higher doses). It is not appropriate for patients with heart failure.

Vitamin E (800 IU/day) — For Non-Diabetic Adults

High-dose Vitamin E (800 IU/day, as alpha-tocopherol) has been studied in non-diabetic adults with biopsy-confirmed NASH. The PIVENS trial showed significant improvement in liver histology — specifically steatosis and inflammation — though fibrosis improvement was modest compared to Rezdiffra.

Limitations: Not recommended in patients with diabetes, prostate cancer history, or coagulation disorders. Long-term use at high doses carries some cardiovascular risk. It does not require a prescription and is inexpensive.

GLP-1 Agonists (Other Than Semaglutide)

Other GLP-1 receptor agonists — such as liraglutide (Victoza) and tirzepatide (Mounjaro) — have shown promise in MASH clinical trials though they are not yet approved for this specific indication. If you already take one of these drugs for diabetes or weight management, your hepatologist may consider it a beneficial adjunct to your liver care.

Lifestyle Interventions — Still the Foundation

Even Rezdiffra is prescribed "in conjunction with diet and exercise." Before pharmacologic therapy was available, weight loss through sustained lifestyle changes was the only proven treatment for MASH. Research consistently shows that achieving 7–10% body weight reduction through diet and exercise significantly reduces liver fat, inflammation, and can even improve fibrosis. Even if you are on Rezdiffra or another medication, lifestyle changes amplify the drug's effects.

What to Ask Your Doctor

If you cannot access Rezdiffra, have this conversation with your hepatologist:

"Would I qualify for semaglutide (Wegovy) for my MASH, given my obesity/diabetes status?"

"Is pioglitazone appropriate for my situation, given my metabolic health?"

"What is my MASH progression risk if I delay treatment while we resolve the insurance issue?"

"Are there any clinical trials I might qualify for?"

Don't Give Up on Rezdiffra Access

Before settling for an alternative, exhaust your options for accessing Rezdiffra. The Madrigal Patient Assistance Program can provide the drug at no cost to qualifying patients. Your hepatologist can appeal insurance denials. And medfinder can help you locate which specialty pharmacies carry it near you. See our full guide: How to Find Rezdiffra in Stock Near You.